{"id":3994,"date":"2023-09-19T08:44:46","date_gmt":"2023-09-19T08:44:46","guid":{"rendered":"https:\/\/www.sygnaturediscovery.com\/poster\/characterising-the-response-of-tumours-to-fractioned-radiotherapy-and-immune-checkpoint-inhibitors\/"},"modified":"2026-01-22T17:16:20","modified_gmt":"2026-01-22T17:16:20","slug":"characterising-the-response-of-tumours-to-fractioned-radiotherapy-and-immune-checkpoint-inhibitors","status":"publish","type":"poster","link":"https:\/\/www.sygnaturediscovery.com\/fr\/poster\/characterising-the-response-of-tumours-to-fractioned-radiotherapy-and-immune-checkpoint-inhibitors\/","title":{"rendered":"Characterising the response of tumours to fractioned radiotherapy and immune checkpoint inhibitors"},"content":{"rendered":"

Do you want to know how radiotherapy and immunotherapy can work together to fight cancer?<\/p>\n

In our latest poster, we explored the effects of different doses and schedules of radiation in combination with immune checkpoint inhibitors on tumour growth in a syngeneic mouse model of colorectal cancer.<\/p>\n

We tested the combination of radiation with immune checkpoint inhibitors and found that fractionated radiation, which is delivered in smaller doses over several days, was more effective and tolerable than a single high dose. With the use of flow cytometry, we characterised the changes in the tumour microenvironment and revealed how radiation and immunotherapy can alter the balance of the infiltrated immune cells.<\/p>\n

Our work provides valuable insights into the mechanisms and outcomes of combining radiotherapy and immunotherapy for cancer treatment. It also offers a useful platform for testing new drugs and novel therapeutics that can potentially improve the efficacy and safety of this combination therapy.<\/p>\n","protected":false},"excerpt":{"rendered":"

In our latest study, we delved into combining radiotherapy and immunotherapy against cancer. Fractionated radiation, given in smaller doses over several days, proved more effective and tolerable than a single high dose. Our work offers insights into this synergy, providing a platform to enhance the therapy’s efficacy and safety.<\/p>\n","protected":false},"featured_media":2658,"template":"","category":[685,751,738,688],"class_list":["post-3994","poster","type-poster","status-publish","has-post-thumbnail","hentry","category-in-vivo-pharmacology","category-oncology","category-oncology-models","category-therapeutic-areas"],"acf":[],"yoast_head":"\nCharacterising The Response of Tumours<\/title>\n<meta name=\"description\" content=\"Explore the synergy of radiotherapy and immunotherapy for cancer. Valuable insights and promising approaches await in our digital poster.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.sygnaturediscovery.com\/fr\/poster\/characterising-the-response-of-tumours-to-fractioned-radiotherapy-and-immune-checkpoint-inhibitors\/\" \/>\n<meta property=\"og:locale\" content=\"fr_CA\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Characterising The Response of Tumours\" \/>\n<meta property=\"og:description\" content=\"Explore the synergy of radiotherapy and immunotherapy for cancer. Valuable insights and promising approaches await in our digital poster.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.sygnaturediscovery.com\/fr\/poster\/characterising-the-response-of-tumours-to-fractioned-radiotherapy-and-immune-checkpoint-inhibitors\/\" \/>\n<meta property=\"og:site_name\" content=\"Sygnature\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-22T17:16:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/11\/TO_EACR2023_IR-capability-poster-1-003-e1744810782784.png\" \/>\n\t<meta property=\"og:image:width\" content=\"888\" \/>\n\t<meta property=\"og:image:height\" content=\"628\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Estimation du temps de lecture\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/poster\\\/characterising-the-response-of-tumours-to-fractioned-radiotherapy-and-immune-checkpoint-inhibitors\\\/\",\"url\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/poster\\\/characterising-the-response-of-tumours-to-fractioned-radiotherapy-and-immune-checkpoint-inhibitors\\\/\",\"name\":\"Characterising The Response of Tumours\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/poster\\\/characterising-the-response-of-tumours-to-fractioned-radiotherapy-and-immune-checkpoint-inhibitors\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/poster\\\/characterising-the-response-of-tumours-to-fractioned-radiotherapy-and-immune-checkpoint-inhibitors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/TO_EACR2023_IR-capability-poster-1-003-e1744810782784.png\",\"datePublished\":\"2023-09-19T08:44:46+00:00\",\"dateModified\":\"2026-01-22T17:16:20+00:00\",\"description\":\"Explore the synergy of radiotherapy and immunotherapy for cancer. Valuable insights and promising approaches await in our digital poster.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/poster\\\/characterising-the-response-of-tumours-to-fractioned-radiotherapy-and-immune-checkpoint-inhibitors\\\/#breadcrumb\"},\"inLanguage\":\"fr-CA\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/poster\\\/characterising-the-response-of-tumours-to-fractioned-radiotherapy-and-immune-checkpoint-inhibitors\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-CA\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/poster\\\/characterising-the-response-of-tumours-to-fractioned-radiotherapy-and-immune-checkpoint-inhibitors\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/TO_EACR2023_IR-capability-poster-1-003-e1744810782784.png\",\"contentUrl\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/TO_EACR2023_IR-capability-poster-1-003-e1744810782784.png\",\"width\":888,\"height\":628},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/poster\\\/characterising-the-response-of-tumours-to-fractioned-radiotherapy-and-immune-checkpoint-inhibitors\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/page-daccueil\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Characterising the response of tumours to fractioned radiotherapy and immune checkpoint inhibitors\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/\",\"name\":\"Sygnature Discovery\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#organization\"},\"alternateName\":\"Sygnature\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-CA\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#organization\",\"name\":\"Sygnature Discovery\",\"url\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-CA\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/Logo.svg\",\"contentUrl\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/Logo.svg\",\"width\":1,\"height\":1,\"caption\":\"Sygnature Discovery\"},\"image\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Characterising The Response of Tumours","description":"Explore the synergy of radiotherapy and immunotherapy for cancer. Valuable insights and promising approaches await in our digital poster.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.sygnaturediscovery.com\/fr\/poster\/characterising-the-response-of-tumours-to-fractioned-radiotherapy-and-immune-checkpoint-inhibitors\/","og_locale":"fr_CA","og_type":"article","og_title":"Characterising The Response of Tumours","og_description":"Explore the synergy of radiotherapy and immunotherapy for cancer. Valuable insights and promising approaches await in our digital poster.","og_url":"https:\/\/www.sygnaturediscovery.com\/fr\/poster\/characterising-the-response-of-tumours-to-fractioned-radiotherapy-and-immune-checkpoint-inhibitors\/","og_site_name":"Sygnature","article_modified_time":"2026-01-22T17:16:20+00:00","og_image":[{"width":888,"height":628,"url":"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/11\/TO_EACR2023_IR-capability-poster-1-003-e1744810782784.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Estimation du temps de lecture":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/poster\/characterising-the-response-of-tumours-to-fractioned-radiotherapy-and-immune-checkpoint-inhibitors\/","url":"https:\/\/www.sygnaturediscovery.com\/fr\/poster\/characterising-the-response-of-tumours-to-fractioned-radiotherapy-and-immune-checkpoint-inhibitors\/","name":"Characterising The Response of Tumours","isPartOf":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/poster\/characterising-the-response-of-tumours-to-fractioned-radiotherapy-and-immune-checkpoint-inhibitors\/#primaryimage"},"image":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/poster\/characterising-the-response-of-tumours-to-fractioned-radiotherapy-and-immune-checkpoint-inhibitors\/#primaryimage"},"thumbnailUrl":"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/11\/TO_EACR2023_IR-capability-poster-1-003-e1744810782784.png","datePublished":"2023-09-19T08:44:46+00:00","dateModified":"2026-01-22T17:16:20+00:00","description":"Explore the synergy of radiotherapy and immunotherapy for cancer. Valuable insights and promising approaches await in our digital poster.","breadcrumb":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/poster\/characterising-the-response-of-tumours-to-fractioned-radiotherapy-and-immune-checkpoint-inhibitors\/#breadcrumb"},"inLanguage":"fr-CA","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.sygnaturediscovery.com\/fr\/poster\/characterising-the-response-of-tumours-to-fractioned-radiotherapy-and-immune-checkpoint-inhibitors\/"]}]},{"@type":"ImageObject","inLanguage":"fr-CA","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/poster\/characterising-the-response-of-tumours-to-fractioned-radiotherapy-and-immune-checkpoint-inhibitors\/#primaryimage","url":"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/11\/TO_EACR2023_IR-capability-poster-1-003-e1744810782784.png","contentUrl":"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/11\/TO_EACR2023_IR-capability-poster-1-003-e1744810782784.png","width":888,"height":628},{"@type":"BreadcrumbList","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/poster\/characterising-the-response-of-tumours-to-fractioned-radiotherapy-and-immune-checkpoint-inhibitors\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.sygnaturediscovery.com\/fr\/page-daccueil\/"},{"@type":"ListItem","position":2,"name":"Characterising the response of tumours to fractioned radiotherapy and immune checkpoint inhibitors"}]},{"@type":"WebSite","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#website","url":"https:\/\/www.sygnaturediscovery.com\/fr\/","name":"Sygnature Discovery","description":"","publisher":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#organization"},"alternateName":"Sygnature","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.sygnaturediscovery.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-CA"},{"@type":"Organization","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#organization","name":"Sygnature Discovery","url":"https:\/\/www.sygnaturediscovery.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-CA","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/11\/Logo.svg","contentUrl":"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/11\/Logo.svg","width":1,"height":1,"caption":"Sygnature Discovery"},"image":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/poster\/3994","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/poster"}],"about":[{"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/types\/poster"}],"version-history":[{"count":0,"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/poster\/3994\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/media\/2658"}],"wp:attachment":[{"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/media?parent=3994"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/category?post=3994"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}